The experiment results show that PLX4720 is able to inhibit the secretion of CXCL8 in BRAFV600E-mutated thyroid cancer cells, which indicated that at least some of the antitumor activities of PLX4720 could be exerted through lowering of CXCL8 in the thyroid cancer microenvironment [35, 36]. This evidence concerns the gene CXCL8 and thyroid gland carcinoma.